ESMO 2023 | Development of a vaccine for pre-treated head & neck squamous cell carcinoma

Nicolas Mach, MD, Hôpitaux Universitaires de Genève, Geneva, Switzerland, gives an overview of MVX-ONCO-1, a novel cancer vaccine for patients with recurrent/metastatic head & neck squamous cell carcinoma (RMHNSCC). The vaccine consists of metastatic tumor cells derived from patients and allogeneic cells. The personalized therapy was assessed in the Phase IIa SAKK 11/16 trial (NCT02999646). This interview took place at the European Society for Medical Oncology (ESMO) 2023 Congress in Madrid, Spain.

These works are owned by Magdalen Medical Publishing (MMP) and are protected by copyright laws and treaties around the world. All rights are reserved.